Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/17/2020 01/21/2020 01/22/2020 01/23/2020 01/24/2020 Date
163.06(c) 163.71(c) 163.77(c) 162.48(c) 162.25(c) Last
2 608 845 2 293 122 1 882 412 2 153 326 1 918 913 Volume
+0.96% +0.40% +0.04% -0.79% -0.14% Change
More quotes
Financials (USD)
Sales 2019 18 181 M
EBIT 2019 3 310 M
Net income 2019 2 601 M
Debt 2019 2 579 M
Yield 2019 0,42%
Sales 2020 21 409 M
EBIT 2020 4 103 M
Net income 2020 3 091 M
Debt 2020 19 576 M
Yield 2020 0,44%
P/E ratio 2019 47,5x
P/E ratio 2020 37,6x
EV / Sales2019 6,57x
EV / Sales2020 6,37x
Capitalization 117 B
More Financials
Company
Danaher Corporation is an industrial and technologic group organized around 4 families of products: - medical equipment (63.8% of net sales): diagnostic equipment, digital imaging systems, optical instruments, microscopes, consumables, etc.; - professional instruments of analysis (12.2%): systems... 
More about the company
Surperformance© ratings of Danaher Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on DANAHER CORPORATION
01/23DANAHER : Announces Updated Time For Fourth Quarter 2019 Earnings Conference Cal..
PR
01/14Global UV Disinfection Equipment Market Projected to Reach $3.4 Billion by 20..
AQ
01/13DANAHER CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
01/13DANAHER : CEO To Comment On Financial Performance
PR
01/09DANAHER : To Present At J.P. Morgan Healthcare Conference
PR
01/07DANAHER : Schedules Fourth Quarter 2019 Earnings Conference Call
PR
2019DANAHER CORPORATION : Ex-dividend day for
FA
2019DANAHER : EU OKs Danaher Acquisition of GE Healthcare's Biopharma Business
DJ
2019Danaher wins conditional EU okay for $21 billion biopharma buy
RE
2019DANAHER CORP /DE/ : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
2019DANAHER CORP /DE/ : Completion of Acquisition or Disposition of Assets, Financia..
AQ
2019DANAHER : Says Envista Exchange Offer Oversubscribed
DJ
2019DANAHER : Announces Quarterly Dividend
PR
2019DANAHER CORP /DE/ : Temporary Suspension of Trading Under Registrant's Employee ..
AQ
2019DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
More news
News in other languages on DANAHER CORPORATION
2019Les fusions-acquisitions soutenues par la vigueur du marché américain en 2019
2019DANAHER CORPORATION : Ex-dividend day for
2019STOCK MARKET PARIS : L'Impeachment visant Trump n'ébranle pas les marchés
2019EN DIRECT DES MARCHES : Société Générale, Atos, Vivendi, Akka, Altran, Invent..
2019L'UE valide sous conditions le rachat par Danaher de l'activité biopharma de ..
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Sector news : Advanced Medical Equipment & Technology - NEC
01/23INTUITIVE SURGICAL : Beats Wall Street Forecasts for 4Q
DJ
01/15BOSTON SCIENTIFIC : Falls on Sales Data
DJ
01/14Boston Scientific On Track for Largest Percent Decrease Since May 2011 -- Dat..
DJ
01/14BOSTON SCIENTIFIC : Shares Fall on Weak Preliminary Sales Numbers -- Update
DJ
01/14BOSTON SCIENTIFIC : Warns of Fourth-Quarter Sales Shortfall
DJ
More sector news : Advanced Medical Equipment & Technology - NEC
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 164,93  $
Last Close Price 162,25  $
Spread / Highest target 17,1%
Spread / Average Target 1,65%
Spread / Lowest Target -26,0%
EPS Revisions
Managers
NameTitle
Thomas Patrick Joyce President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer
Alan G. Spoon Independent Director
Donald Jerry Ehrlich Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER CORPORATION5.86%116 836
THERMO FISHER SCIENTIFIC3.24%133 803
INTUITIVE SURGICAL, INC.-0.33%68 096
BOSTON SCIENTIFIC CORPORATION-4.44%60 227
SIEMENS HEALTHINEERS5.31%49 628
EDWARDS LIFESCIENCES CORPORATION-1.22%48 065